Medical Oncology

Uzm. Dr. Beliz Bahar Karaoğlan

Doctor and researcher Eskişehir Şehir Hastanesi Eskişehir
Colorectal NeoplasmsNeoplasmsColonic Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Colorectal Neoplasms 5 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Neoplasms 4 publications
  • Colonic Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionEskişehir Şehir Hastanesisaglik.gov.trFrom source
  • Area of workColorectal NeoplasmsExtracted from 5 publications · Model version —From source
  • Publications39 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-5021-7588ORCIDFrom source
  • Last synchronised7 November 2026 00:21https://eskisehirsehir.saglik.gov.tr/TR-604583/doktorlarimiz.html#beliz-bahar-karaoglansaglik.gov.tr

Scientific work

Publications on Colorectal Neoplasms

39 publications
Publications by year Most: 17, in 2025
  1. 2023: 2 publications
  2. 2024: 12 publications
  3. 2025: 17 publications
  4. 2026: 8 publications

  1. Survival Outcomes in ERBB2- Low vs ERBB2- Null Advanced Gastric Cancer

    JAMA Network Open, 2026

    DOI 10.1001/jamanetworkopen.2026.24180 PMID 42479431 Open-access full textSource: OpenAlex

  2. Aspirin use and outcomes with immune checkpoint inhibitors in metastatic cancer.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e14584 1 citation (OpenAlex) Source: OpenAlex

  3. Concordance Between ChatGPT and Real-World Adjuvant Chemotherapy Decisions in pT3N0 Colon Cancer

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612508 Source: ORCID

  4. Reevaluating regorafenib: Do we need the full dose?

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1874059 Open-access full textSource: ORCID

  5. Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI

    Cancers, 2026

    DOI 10.3390/cancers18050852 PMID 41827785 9 citations (Europe PMC) Open-access full textSource: ORCID

  6. Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study

    Figshare, 2026

    DOI 10.6084/m9.figshare.31064068 Open-access full textSource: OpenAlex

  7. Midday immune checkpoint inhibitor (ICI) infusion influence on survival in patients with metastatic cancer: A real-world chrono-immunotherapy study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.11162 Open-access full textSource: OpenAlex

  8. 510P Clinical and molecular characterization of HER2-low gastroesophageal adenocarcinoma: Multicenter cohort data

    Annals of Oncology, 2026

    DOI 10.1016/j.annonc.2026.05.550 Open-access full textSource: OpenAlex

  9. Efficacy of anti-VEGF & anti-EGFRs in microsatellite instable (MSI-H) metastatic colorectal cancer, Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e15507 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  10. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

    Current Oncology, 2025

    DOI 10.3390/curroncol32110639 PMID 41294701 1 citation (Europe PMC) Open-access full textSource: OpenAlex

View all 39 publications